Prediction of future tau accumulation and cognitive decline in Down Syndrome using plasma biomarkers
Baseline plasma pTau217 predicted subsequent decline in global cognition and progression to dementia, whereas both pTau217 and GFAP were associated with an increase in tau burden. Longitudinal increase in pTau217 levels was associated with accelerated cognitive decline and tau deposition. These findings suggest that blood pTau217, potentially together with GFAP, could support the prognostic workup of AD in individuals with DS in both clinical practice and trials.
Authors
- Lyduine E. Collij (ORCID: https://orcid.org/0000-0001-6263-1762)
- Benjamin L. Handen (ORCID: https://orcid.org/0000-0001-9550-1665)
- Charles M. Laymon (ORCID: https://orcid.org/0000-0002-5966-7219)
- Rik Ossenkoppele (ORCID: https://orcid.org/0000-0003-1584-7477)
- Sigan L. Hartley (ORCID: https://orcid.org/0000-0002-0186-6282)
- Florence Lai (ORCID: https://orcid.org/0000-0003-4354-0624)
- Davneet Minhas (ORCID: https://orcid.org/0000-0002-0217-6777)
- Beau M. Ances (ORCID: https://orcid.org/0000-0003-3862-7397)
- Shahid Zaman
- Alex Antill (ORCID: https://orcid.org/0009-0008-3670-8656)
- Ira T. Lott (ORCID: https://orcid.org/0000-0002-3107-0752)
- Oskar H. Hansson
- Bradley T Christian
- Niklas Mattsson‐Carlgren
- Weiquan Luo
- Mark Mapstone
- Shorena Janelidze
- H. Diana Rosas
Institutions
- University of Wisconsin–Madison (US)
- University of Pittsburgh (US)
- Lund University (SE)
- University of California, Irvine (US)
- Washington University in St. Louis (US)
- University of Cambridge (GB)
- Massachusetts General Hospital (US)
- Skåne University Hospital (SE)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099360
- Primary Topic
- Down syndrome and intellectual disability research
- Type
- article
- Field-Weighted Citation Impact
- 0.00